| Drug Name |
Dacarbazine |
| Drug ID |
BADD_D00568 |
| Description |
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. |
| Indications and Usage |
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01AX04 |
| DrugBank ID |
DB00851
|
| KEGG ID |
D00288
|
| MeSH ID |
D003606
|
| PubChem ID |
2942
|
| TTD Drug ID |
D0Y7ZU
|
| NDC Product Code |
42973-149; 63323-128; 0143-9245; 0703-5075; 54875-0003; 63323-127 |
| UNII |
7GR28W0FJI
|
| Synonyms |
Dacarbazine | Dimethyl Imidazole Carboxamide | Carboxamide, Dimethyl Imidazole | Imidazole Carboxamide, Dimethyl | DTIC | ICDT | Decarbazine | 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide | DIC | Dimethyl Triazeno Imidazole Carboxamide | NSC-45388 | NSC 45388 | NSC45388 | DTIC-Dome | DTIC Dome | DTICDome | Biocarbazine | Deticene |
